{"nctId":"NCT00391807","briefTitle":"Study of Safety and Efficacy of an Oral Contraceptive","startDateStruct":{"date":"2006-11"},"conditions":["Contraception"],"count":1683,"armGroups":[{"label":"study drug","type":"EXPERIMENTAL","interventionNames":["Drug: Norethindrone acetate/ethinyl estradiol"]}],"interventions":[{"name":"Norethindrone acetate/ethinyl estradiol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy Women\n* Age 18-45\n* At risk for pregnancy\n* History of regular cycles\n\nExclusion Criteria:\n\n* Contraindications for use of hormonal contraception\n* Conditions which affect the absorption or metabolism of steroid hormones\n* BMI \\> 35","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.554","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 2, MITT Population","description":"MITT Population","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.21","spread":"4.15"}]}]}]},{"type":"PRIMARY","title":"Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45, MITT Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.167","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 6, MITT Population","description":"MITT Population","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"3.12"}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 13, MITT Population","description":"MITT Population","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"3.01"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Withdrawal Bleeding (%), Cycle 2, MITT Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Withdrawal Bleeding (%), Cycle 6, MITT Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Withdrawal Bleeding (%), Cycle 13, MITT Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Duration of Withdrawal Bleeding, Cycle 2, MITT Population","description":null,"paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","spread":"2.18"}]}]}]},{"type":"SECONDARY","title":"Median Duration of Withdrawal Bleeding, Cycle 6, MITT Population","description":null,"paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.99","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Median Duration of Withdrawal Bleeding, Cycle 12, MITT Population","description":null,"paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.85","spread":"2.07"}]}]}]},{"type":"SECONDARY","title":"Total Number of Bleeding Days Per Cycle, Cycle 2, MITT Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.57","spread":"4.94"}]}]}]},{"type":"SECONDARY","title":"Total Number of Bleeding Days Per Cycle, Cycle 6, MITT Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":"3.73"}]}]}]},{"type":"SECONDARY","title":"Total Number of Bleeding Days Per Cycle, Cycle 13, MITT Population","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.36","spread":"4.51"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Amenorrhea, Cycle 2, MITT Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Amenorrhea, Cycle 6, MITT Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Amenorrhea, Cycle 13, MITT Population","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":1660},"commonTop":["Headache","Upper Respiratory Tract Infection","Sinusitis","Nasopharyngitis"]}}}